Jpmorgan Chase & CO Evaxion Biotech A/S Call Options Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding EVAX

# of Institutions
1
Shares Held
37.5K
Call Options Held
0
Put Options Held
0
View Full List

About Evaxion Biotech A/S

EVAX Quotes by TradingView
  • Ticker EVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,977,900
  • Market Cap $20.4M
  • Description
  • Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Ph...
More about EVAX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email